FDA Requests Removal of Opana ER for Risks Related to Abuse

June 8, 2017 -- Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news